title: Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study.
abstract: BACKGROUND
  Monoclonal antibodies to the pro-inflammatory cytokine tumour necrosis factor-alpha have shown efficacy in treating Crohn's disease, but can be immunogenic. Soluble tumour necrosis factor-binding proteins are being studied as potential alternative anti-tumour necrosis factor agents in Crohn's disease.
  
  
  OBJECTIVE
  To investigate the safety and efficacy of onercept, a recombinant form of the natural human soluble p55 tumour necrosis factor receptor, in the treatment of patients with active Crohn's disease.
  
  
  METHODS
  In a pilot study, 12 patients with active Crohn's disease were randomized to receive onercept at either 11.7 or 50 mg three times weekly for 2 weeks. Patients were followed up for 6 months after the end of treatment.
  
  
  RESULTS
  The Crohn's disease activity index decreased rapidly during treatment in both groups. Seven responses (Crohn's disease activity index decrease of 100 points) were observed over the first 6 weeks of the study, including five remissions (Crohn's disease activity index decrease of 150 points). Improvement was sustained for 2-4 months after stopping treatment. Treatment was well tolerated. No patients developed antibodies to onercept.
  
  
  CONCLUSIONS
  Neutralizing the activity of tumour necrosis factor-alpha with its soluble p55 receptor may be valuable in the treatment of patients with Crohn's disease. Larger placebo-controlled trials are indicated.
authors.affiliation: University Hospital Gasthuisberg, Leuven, Belgium. PaulRutgeerts.uz.kuleuven.ac.be
authors.forename: P
authors.initials: P
authors.lastname: Rutgeerts
authors.forename: L
authors.initials: L
authors.lastname: Lemmens
authors.forename: G
authors.initials: G
authors.lastname: Van Assche
authors.forename: M
authors.initials: M
authors.lastname: Noman
authors.forename: I
authors.initials: I
authors.lastname: Borghini-Fuhrer
authors.forename: R
authors.initials: R
authors.lastname: Goedkoop
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002352:Carrier Proteins / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D016896:Treatment Outcome; D053319:Tumor Necrosis Factor Decoy Receptors
chemical_list: D000893:Anti-Inflammatory Agents; D002352:Carrier Proteins; D005765:Gastrointestinal Agents; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D053319:Tumor Necrosis Factor Decoy Receptors; C069521:recombinant human tumor necrosis factor-binding protein-1